January 2019 Issue Table Of Contents

From The Editor

• Another Year Older, But Are We Another Year Wiser?

Feature Articles

• How Halozyme’s First-Time CEO Financed Drug Development
• Three “Others” Of The New Oncology

Capitol Perspectives

• Rx Industry Under Multifront Siege

CEO Corner

• Turning The Ocean Liner: How To Advocate For A Breakthrough Treatment Paradigm

From Principles and Policy to Execution

• Planning, Pre-Emption, Prevention Make Good Policy Prescriptions

Companies To Watch

• Synspira

Industry Research

• Clinical Research M&A: A Slower Year

Inside The Industry

• Big Pharma’s Unique Approaches To Leadership Development
• How Biopharma & Medtech CFOs Are Viewing U.S. Tax Reform
• From Industry 4.0 To Pharma 4.0
• Germany’s Plan To Foster And Grow Biopharma Innovation
• Is China’s Golden Era Ending?
• 2019: The Year Of Value-based Healthcare
• From Lab To Lawsuit: Litigation Risks In Pharma-Licensing Agreements
• The Unique Challenges Facing Cannabis-based Pharma
• Blockchain’s Challenging Path To Enhancing Clinical Trials

Industry Leader

• Beyond Capital and Mentoring: Paving The Way For Female Entrepreneurs

Leadership Lessons

• 5 Ways To Focus In A Distracting World

Ask The Board

• How Would “Medicare For All” Be Financed?
• How Have Current Tensions Between Mexico And The White House Impacted Biopharma Manufacturing Operations Located In Mexico?
• How Do Leaders Transition From A Functional Role To A GM-Like Role?